Lv11
60 积分 2023-03-21 加入
A tool for analyzing complex epitope binning data of monoclonal antibodies
6天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
21天前
已完结
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
26天前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
2个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
2个月前
已完结
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
4个月前
已完结
VP4-2024: First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
4个月前
已完结
Low-dose interleukin-2 therapy in autoimmune and inflammatory diseases: facts and hopes
5个月前
已完结
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
5个月前
已完结
皖公网安备34019202002308
